Beilstein J. Nanotechnol.2014,5, 313–322, doi:10.3762/bjnano.5.35
hyperthermia (HT). HT is currently used in clinical trials for cancer therapy in combination with radiotherapy and chemotherapy. One of the potential problems of HT is that it can up-regulate hypoxia-inducible factor-1 (HIF-1) expression and enhance vascular endothelial growth factor (VEGF) secretion.
Results
of both transcription factors.
Keywords: hypoxia-inducible factor-1; IR820; nanoparticle; poly(glycerol malate co-dodecanedioate) (PGMD); vascular endothelial growth factor; Introduction
The synthesis and development of novel polymers and their use for nanoparticle (NP) synthesis has been an
endothelial growth factor (VEGF), and poor lymphatic clearance from tumor sites [4]. Because of these advantages, we synthesized a new formulation of polymeric NPs for image-guided therapy based on the polymer poly(glycerol malate co-dodecanedioate) (PGMD) developed in our lab. The work described in this
PDF
Figure 1:
Subcellular localization of free IR820 (A) and IR820-PGMD NPs (B) in SKOV-3 after 24-hour incubatio...
Beilstein J. Nanotechnol.2012,3, 759–772, doi:10.3762/bjnano.3.85
diffuses into the diseased cell resulting in cell death.
Several factors need to be considered for the successful use of nanoparticles in targeted drug delivery. Biological barriers, including physical surfaces and the reticulo-endothelial system (RES), which detects and sequesters blood-borne particles
PDF
Figure 1:
(a) Schematic of drug-carrying nanoparticles targeting cancer cells and releasing their therapeutic...